Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, talks on the future of immunotherapy for melanoma. Melanoma is highly reactive to immunotherapy and can provide clues as to how to best use immunotherapy to treat other solid tumors. Dr Hamid discusses a variety of therapeutic targets and novel treatments that are currently being investigated, including using lymphocyte activation gene-3 (LAG3) as a predictive marker, tumor infiltrating lymphocytes (TILs), bispecific therapies, and the development of CAR T-cell therapy in solid tumors. Dr Hamid also discusses the novel possibilities for treating leptomeningeal disease. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
